EGFR and adenocarcinoma: STAT3 is persistently activated in about 50% of NSCLCs, especially in adenocarcinomas harboring activating mutations in EGFR which activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation [52, 53].